Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
39 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Hospital in Arizona
Phoenix, Arizona, United States
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Usc Norris Oncology/hematology-Newport Beach
Newport Beach, California, United States
- Stanford Cancer Institute Palo Alto
Palo Alto, California, United States
- Keck Medical Center of Usc Pasadena
Pasadena, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Uchealth University of Colorado Hospital
Aurora, Colorado, United States
- Mayo Clinic in Florida
Jacksonville, Florida, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- University of Kansas Clinical Research Center
Fairway, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- University of Kentucky/markey Cancer Center
Lexington, Kentucky, United States
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Wayne State University/karmanos Cancer Institute
Detroit, Michigan, United States
- Weisberg Cancer Treatment Center
Farmington Hills, Michigan, United States
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
- Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, United States
- Siteman Cancer Center at Christian Hospital
St Louis, Missouri, United States
- Siteman Cancer Center-South County
St Louis, Missouri, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Nebraska Medicine-Bellevue
Bellevue, Nebraska, United States
- Nebraska Medicine-Village Pointe
Omaha, Nebraska, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Case Western Reserve University
Cleveland, Ohio, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, United States
- Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
- University of Virginia Cancer Center
Charlottesville, Virginia, United States
- University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2017
- Primary completion
- 21 Apr 2023
- Completion
- 25 Apr 2023
- Last update posted
- 3 Mar 2025
- Registered enrollment
- 87
- Registry id
- NCT02567409
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.